Payment overview · 2025
General Payments
$739.58
20 reported records · 15 companies
Healthcare provider profile · identity verified
Joseph Dumba, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · OMAHA, NE · NPI 1417007402
Verified facts
What the public records show
CMS Open Payments records show Joseph Dumba, M.D. received $739.58 in general payments during 2025 across 20 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $317.44 | 42.9% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $119.04 | 16.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $60.95 | 8.2% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $46.31 | 6.3% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $22.47 | 3.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.39 | 3.0% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $21.77 | 2.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.93 | 2.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.75 | 2.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.45 | 2.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.86 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.38 | 2.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.65 | 2.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.69 | 1.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.50 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $739.58 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $197.47 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $195.71 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $119.04 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $46.31 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $37.38 | 2 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 411 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 374 | 78 |
| Gabapentin | Gabapentin | 364 | 68 |
| Baclofen | Baclofen | 339 | 38 |
| Myrbetriq | Mirabegron | 280 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 275 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 255 | 56 |
| Sertraline Hcl | Sertraline Hcl | 231 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 224 | 39 |
| Furosemide | Furosemide | 216 | 47 |
| Simvastatin | Simvastatin | 208 | 36 |
| Levetiracetam | Levetiracetam | 195 | 19 |
| Lisinopril | Lisinopril | 175 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 174 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 33 |
| Alprazolam | Alprazolam | 171 | 47 |
| Trazodone Hcl | Trazodone Hcl | 164 | 23 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 162 | 26 |
| Celecoxib | Celecoxib | 159 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 159 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 149 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 149 | 25 |
| Metformin Hcl | Metformin Hcl | 136 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 24 |
| Xarelto | Rivaroxaban | 122 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 19 |
| Carvedilol | Carvedilol | 101 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 32 |
| Carbamazepine | Carbamazepine | 99 | suppressed |
| Meloxicam | Meloxicam | 97 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 16 |
| Alendronate Sodium | Alendronate Sodium | 96 | 15 |
| Lorazepam | Lorazepam | 95 | 19 |
| Mirtazapine | Mirtazapine | 95 | 13 |
| Tramadol Hcl | Tramadol Hcl | 93 | 45 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 88 | 17 |
| Montelukast Sodium | Montelukast Sodium | 87 | 16 |
| Divalproex Sodium | Divalproex Sodium | 86 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 84 | 12 |
| Eliquis | Apixaban | 81 | 17 |
| Risperidone | Risperidone | 77 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 75 | suppressed |
| Potassium Chloride | Potassium Chloride | 75 | 18 |
| Buspirone Hcl | Buspirone Hcl | 71 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 71 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 16 |
| Famotidine | Famotidine | 68 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 67 | 12 |
| Ibuprofen | Ibuprofen | 66 | 30 |
| Bupropion Xl | Bupropion Hcl | 65 | suppressed |
| Losartan Potassium | Losartan Potassium | 64 | 20 |
| Prednisone | Prednisone | 64 | 30 |
| Allopurinol | Allopurinol | 63 | 13 |
| Propranolol Hcl | Propranolol Hcl | 63 | 11 |
| Clonazepam | Clonazepam | 59 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | suppressed |
| Methylprednisolone | Methylprednisolone | 59 | 49 |
| Lamotrigine | Lamotrigine | 58 | suppressed |
| Zonisamide | Zonisamide | 57 | suppressed |
| Linzess | Linaclotide | 56 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 33 |
| Clonidine Hcl | Clonidine Hcl | 55 | 11 |
| Scopolamine | Scopolamine | 55 | suppressed |
| Glimepiride | Glimepiride | 54 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 53 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 24 |
| Glipizide | Glipizide | 51 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 51 | suppressed |
| Azithromycin | Azithromycin | 49 | 41 |
| Olanzapine | Olanzapine | 48 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 46 | 16 |
| Ondansetron Odt | Ondansetron | 45 | 18 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Nexium | Esomeprazole Magnesium | 44 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 44 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Lacosamide | Lacosamide | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 41 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 11 |
| Carbamazepine Er | Carbamazepine | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 37 | suppressed |
| Latanoprost | Latanoprost | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 34 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Lubiprostone | Lubiprostone | 29 | suppressed |
| Methimazole | Methimazole | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | 11 |
| Topiramate | Topiramate | 28 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Nyamyc | Nystatin | 26 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 24 | suppressed |
| Nystatin | Nystatin | 24 | 12 |
| Lumigan | Bimatoprost | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 17 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Roflumilast | Roflumilast | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Trospium Chloride | Trospium Chloride | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Phenytoin | Phenytoin | 18 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Renacidin | Citric Ac/Gluconolact/Mag Carb | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Budesonide | Budesonide | 16 | suppressed |
| Letrozole | Letrozole | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 11 |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 14 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 14 | suppressed |
| Mirabegron Er | Mirabegron | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Temazepam | Temazepam | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Mercaptopurine | Mercaptopurine | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Sodium Fluoride | Fluoride (Sodium) | 12 | suppressed |
| Tyrvaya | Varenicline Tartrate | 12 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $739.58 · 20 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, INSPIRE, ISTURISA, JARDIANCE, Kerendia, LEQVIO, PAXLOVID, REXULTI, Tymlos, VYNDAMAX, WATCHMAN FLX, Wegovy | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error